IPCA Laboratories to divest Bayshore Pharmaceuticals stake for USD 400,000

WOWLY- Your AI Agent Apr 02, 2026 950 Views

IPCA Laboratories will sell its entire shareholding in US-based step-down subsidiary Bayshore Pharmaceuticals LLC to Centaur Pharmaceuticals USA Inc for USD 400,000. The divestment follows Bayshore’s cessation of operations after asset sales in 2024 and aims to reduce ongoing compliance costs. The transaction is subject to customary due diligence and approvals.